ACE Inhibitor Initial Dosing for Hypertension
For first-line ACE inhibitor therapy in hypertension, start with low doses and titrate upward: enalapril 2.5-5 mg once daily, lisinopril 2.5-5 mg once daily, ramipril 1.25-2.5 mg once daily, or perindopril 2-4 mg once daily, with target doses of enalapril 10-20 mg twice daily, lisinopril 20-40 mg daily, ramipril 10 mg daily, or perindopril 8-16 mg daily. 1
Starting Doses by Specific Agent
The KDOQI guidelines provide the most comprehensive dosing table for ACE inhibitors 1:
Common Starting Regimens:
- Enalapril: Start 5 mg daily → Target 10-40 mg daily in 1-2 divided doses
- Lisinopril: Start 10 mg daily → Target 20-40 mg daily
- Ramipril: Start 1.25 mg daily (or 2.5 mg if normal renal function) → Target 1.25-20 mg daily
- Perindopril: Start 4 mg daily → Target 4-16 mg daily in 1-2 divided doses
- Quinapril: Start 10-20 mg daily → Target 20-80 mg daily
- Benazepril: Start 10 mg daily → Target 20-40 mg daily
- Captopril: Start 6.25-25 mg three times daily → Target 25-150 mg 2-3 times daily
Clinical Context for ACE Inhibitors as First-Line
ACE inhibitors are recommended as first-line monotherapy for hypertension in nonblack patients younger than 60 years (Grade B) 2, 3. They should not be used as first-line in black patients with uncomplicated hypertension (Grade A) 2.
When to Use Lower Starting Doses
Exercise caution and start at the lower end of dosing ranges in patients with:
- Systolic blood pressure <80 mm Hg
- Serum creatinine >3 mg/dL
- Bilateral renal artery stenosis
- Serum potassium >5.0 mEq/L
- Elderly or frail patients
- Volume depletion 4
Titration Strategy
The dose-response curve for ACE inhibitors is relatively flat 5. Research shows that:
- 1/2 of maximum dose achieves 90% of the blood pressure lowering effect
- 1/4 to 1/8 of maximum dose achieves 60-70% of maximum effect
- Doses above manufacturer's maximum do not significantly lower BP further 5
Average trough BP lowering for ACE inhibitors as a class: -8/-5 mm Hg at half-maximum dose and above 5.
Practical Titration Approach
- Start low: Use the starting doses listed above
- Assess at 1-2 weeks: Check renal function and serum potassium, especially in patients with pre-existing hypotension, hyponatremia, diabetes, azotemia, or those taking potassium supplements 4
- Titrate gradually: Increase dose every 2-4 weeks if BP not at target and medication well-tolerated
- Target doses: Aim for doses proven in clinical trials (listed above), though 60-70% of BP effect occurs at starting doses 5
Combination Therapy Considerations
For patients with stage 2 hypertension (SBP ≥140 mm Hg and DBP ≥90 mm Hg), consider initiating with two first-line agents, ideally as a single-pill combination 6, 7.
Preferred combinations with ACE inhibitors:
- ACE inhibitor + dihydropyridine calcium channel blocker (Grade A for combination) 3, 6
- ACE inhibitor + thiazide/thiazide-like diuretic (Grade B-C) 2
Never combine ACE inhibitor + ARB - this is not recommended due to potential for harm (Grade A) 2, 6.
Key Monitoring Parameters
- Renal function and potassium: Check within 1-2 weeks of initiation and periodically thereafter 4
- Blood pressure response: Most patients require >1 agent to reach target 8, 6
- Cough: Occurs in up to 20% of patients; if intolerable, switch to ARB 4
- Angioedema: Rare (<1%) but life-threatening; more common in black patients; absolute contraindication to future ACE inhibitor use 4
Common Pitfalls
- Underdosing: Many patients receive submaximal doses despite tolerating higher doses 9. While 60-70% of effect occurs at starting doses, titrate to target doses when possible for optimal cardiovascular protection.
- Not checking labs: Failure to monitor potassium and creatinine within 1-2 weeks can miss important adverse effects 4
- Using in wrong populations: ACE inhibitors are not first-line in black patients with uncomplicated hypertension 2
- Pregnancy: Absolute contraindication - causes fetal/neonatal morbidity and mortality 4, 10